This is a summary of the European public assessment report (EPAR) for Cystadrops. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cystadrops. For practical information about using Cystadrops, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
Therapeutic Area (MeSH)
ATC Code
S01XA21
ATC Item
mercaptamine
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| mercaptamine hydrochloride | N/A | A-0003 |
EMA Name
Cystadrops
Medicine Name
Cystadrops
Aliases
N/ANo risk management plan link.
